SERB Pharmaceuticals agreed to acquire exclusive rights to develop and sell Hansa Biopharma's kidney transplant drug Idefirix in Europe and MENA for $115 million. The deal expands commercialization rights for a key biotech asset and provides Hansa with upfront value from its transplant therapy. The transaction is positive for both companies and could move the stocks modestly.
SERB Pharmaceuticals agreed to acquire exclusive rights to develop and sell Hansa Biopharma's kidney transplant drug Idefirix in Europe and MENA for $115 million. The deal expands commercialization rights for a key biotech asset and provides Hansa with upfront value from its transplant therapy. The transaction is positive for both companies and could move the stocks modestly.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
